BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 9, 2017, Jerome Zeldis retired as a member of the board of directors (the “Board”) of BioSig Technologies, Inc. (the “Company”), which became effective on November 9, 2017 (the “Effective Date”). Dr. Zeldis’ departure was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, or any other matter.
On the Effective Date, the Board appointed Andrew Filler as a director of the Company, effective as of the Effective Date, to serve for a term expiring at the next annual meeting of the Company’s stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal. On November 1, 2017, the Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing.In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a fully-vested three-year option to purchase up to $300,000 of the Company’s common stock at an exercise of $1.63 per share of common stock. Mr. Filler is the general counsel of Sherpa. to the Agreement, the Company, among other things, agreed to propose at an upcoming meeting of the Board that Mr. Filler join the Board as a director of the Company.
Item 8.01Other Events.
On November 10, 2017, the Company issued a press release announcing the appointment of Mr. Filler to the Board.A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Press Release dated November 10, 2017
|
BioSig Technologies, Inc. ExhibitEX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IP veteran Andrew Filler joins BioSig Technologies’ Board of Directors Santa Monica,…To view the full exhibit click here
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.
